

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT8289387

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MORGAN STANLEY SENIOR FUNDING, INC.	11/15/2023
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ALKERMES PHARMA IRELAND LIMITED
<b>Street Address:</b>	ONE BURLINGTON ROAD
<b>Internal Address:</b>	CONNAUGHT HOUSE
<b>City:</b>	DUBLIN 4
<b>State/Country:</b>	IRELAND
<b>PROPERTY NUMBERS Total: 9</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17315973
Application Number:	17315974
Application Number:	13911827
Application Number:	14182536
Application Number:	15218193
Application Number:	16519231
Application Number:	16897920
Application Number:	17072725
Application Number:	17568281
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)646-8646
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	16176468000
<b>Email:</b>	Lynn.Silva@WolfGreenfield.com, Michelle.Quinn@WolfGreenfield.com
<b>Correspondent Name:</b>	JAMES H. MORRIS
<b>Address Line 1:</b>	WOLF, GREENFIELD AND SACKS, P.C.
<b>Address Line 2:</b>	600 ATLANTIC AVENUE
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02210
<b>ATTORNEY DOCKET NUMBER:</b>	A1423.90001US00

<b>NAME OF SUBMITTER:</b>	LYNN M. SILVA
<b>SIGNATURE:</b>	/Lynn M. Silva/
<b>DATE SIGNED:</b>	11/21/2023
<b>Total Attachments: 5</b> source=Alkermes - IPA142390001US00 -SECINT-2-JHM#page1.tif source=Alkermes - IPA142390001US00 -SECINT-2-JHM#page2.tif source=Alkermes - IPA142390001US00 -SECINT-2-JHM#page3.tif source=Alkermes - IPA142390001US00 -SECINT-2-JHM#page4.tif source=Alkermes - IPA142390001US00 -SECINT-2-JHM#page5.tif	

**PARTIAL RELEASE OF SECURITY INTEREST IN PATENTS**

This Partial Release of Security Interest in Patents (this “**Release**”) is granted effective as of the November 15, 2023, by Morgan Stanley Senior Funding, Inc. (“**Morgan Stanley**”), as collateral agent for the Secured Parties under the security agreements referenced below, in favor of Alkermes Pharma Ireland Limited, a private limited company incorporated in Ireland (registered number 448848) whose registered office is at Connaught House, 1 Burlington Road, Dublin, Ireland D04 C5Y6 (“**APIL**”) (each, a “**Party**” and, collectively, the “**Parties**”).

**W I T N E S S E T H :**

WHEREAS, Alkermes, Inc., a corporation organized under the laws of the Commonwealth of Pennsylvania, APIL and Morgan Stanley are party to a First Lien Guarantee and Collateral Agreement dated as of September 16, 2011, as amended on September 25, 2012, in favor of Morgan Stanley (the “**Collateral Agreement**”);

WHEREAS, pursuant to the Collateral Agreement, APIL granted to Morgan Stanley a security interest in and to certain Patent Collateral (as defined in the Patent Security Agreements (as defined below));

WHEREAS, pursuant to the Collateral Agreement, APIL entered into (a) a Patent Security Agreement, dated as of June 10, 2014, in favor of Morgan Stanley, which was recorded with the U.S. Patent and Trademark Office (the “**USPTO**”) on June 25, 2014 at Reel/Frame 033244/0499; (b) a Patent Security Agreement, dated as of November 16, 2016, in favor of Morgan Stanley, which was recorded with the USPTO on May 3, 2018 at Reel/Frame 045711/0636; (c) a Patent Security Agreement, dated as of March 17, 2020, in favor of Morgan Stanley, which was recorded with USPTO on March 20, 2020 at Reel/Frame 052174/0842; (d) a Patent Security Agreement, dated as of April 2, 2021, in favor of Morgan Stanley, which was recorded with the USPTO on July 17, 2023 at Reel/Frame 064286/0597; (e) a Patent Security Agreement, dated as of February 28, 2022, in favor of Morgan Stanley, which was recorded with USPTO on July 17, 2023, at Reel/Frame 064286/0821 (subclauses (a) through (e), collectively, the “**Patent Security Agreements**”); and

WHEREAS, in accordance with the applicable provisions of the Collateral Agreement, Morgan Stanley desires to release any and all security interests, and any other lien, it has in the Patent Collateral set forth on Schedule A (the “**Released Patent Collateral**”).

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Morgan Stanley hereby agrees as follows:

1. Morgan Stanley hereby (i) absolutely, unconditionally and irrevocably terminates, extinguishes, cancels, forever discharges and releases each security interest it has in the Released Patent Collateral, including the security interests that were granted to Morgan Stanley under the Patent Security Agreements and the Collateral Agreement, and any and all right, title and interest of Morgan Stanley in the Released Patent Collateral shall hereby terminate, cease and become void, and (ii) re-assigns to APIL any and all right,


title or interest Morgan Stanley may have in such Released Patent Collateral. For the avoidance of doubt, this Release shall be applicable only and solely to the Released Patent Collateral, and shall not apply in any respect to any other Patent Collateral. Morgan Stanley retains all other security interests pledged and granted to Morgan Stanley under the Collateral Agreement and the Patent Security Agreements.

2. The Parties hereto authorize and request that the Director of Patents and Trademarks of the United States of America record this Release against the Released Patent Collateral. Morgan Stanley agrees to perform, at APIL's expense, all further acts and execute and deliver all further documents and/or instruments that may be reasonably necessary to fully and effectively carry out the purposes of this Release.
3. This Release shall be governed by and construed in accordance with the law of the State of New York.
4. This Release shall be binding upon Morgan Stanley's representatives, successors, assigns and transferees.

**[Remainder of Page Intentionally Blank]**

IN WITNESS WHEREOF, the undersigned has caused this Partial Release of Security Interest in Patents to be executed by its duly authorized representatives as of the date first above written.

MORGAN STANLEY SENIOR FUNDING, INC.

By   
Name: Lisa Hanson  
Title: Authorized Signatory  
Date: November 15, 2023

## **SCHEDULE A**

Released Patent Collateral:

<b>Patent Title</b>	<b>Application No.</b>	<b>Registration No.</b>	<b>Issue Date</b>
IL-2 FUSION POLYPEPTIDE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME	17/315,973	N/A	N/A
METHODS OF PURIFICATION	62/965,578	N/A	N/A
IL-2 FUSION POLYPEPTIDE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME	17/315,974	N/A	N/A
LIGANDS MODIFIED BY CIRCULAR PERMUTATION AS AGONISTS AND ANTAGONISTS	13/911,827	9,359,415	07 June 2016
LIGANDS MODIFIED BY CIRCULAR PERMUTATION AS AGONISTS AND ANTAGONISTS	14/182,536	9,428,563	30 August 2016
LIGANDS MODIFIED BY CIRCULAR PERMUTATION AS AGONISTS AND ANTAGONISTS	15/218,193	10,407,481	10 September 2019
LIGANDS MODIFIED BY CIRCULAR PERMUTATION AS AGONISTS AND ANTAGONISTS	16/519,231	N/A	N/A
COMPOSITIONS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF CANCER IMMUNOTHERAPY	62/924,356	N/A	N/A
COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY	62/932,160	N/A	N/A

Patent Title	Application No.	Registration No.	Issue Date
IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS	63/010,185	N/A	N/A
COMPOSITIONS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF CANCER IMMUNOTHERAPY	16/897,920	11,246,906	15 February 2022
IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS	62/916,936	N/A	N/A
IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS	17/072,725	11,248,050	15 February 2022
IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS	17/568,281	N/A	N/A
COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY	63/309,199	N/A	N/A